Publications by authors named "Gideon Bollag"

73Publications

Inhibition of TAMs improves the response to docetaxel in castration-resistant prostate cancer.

Endocr Relat Cancer 2019 01;26(1):131-140

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California at Los Angeles, Los Angeles, California, USA.

View Article and Find Full Text PDF
January 2019

An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling.

Cancer Cell 2016 09 11;30(3):485-498. Epub 2016 Aug 11.

Department of Oncological Sciences, Department of Dermatology, The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA. Electronic address:

View Article and Find Full Text PDF
September 2016

Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAF melanoma.

Oncoimmunology 2016 Mar 10;5(3):e1089381. Epub 2015 Dec 10.

Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland Australia; School of Medicine, The University of Queensland, Herston, Queensland, Australia.

View Article and Find Full Text PDF
March 2016

KRAS Engages AGO2 to Enhance Cellular Transformation.

Cell Rep 2016 Feb 4;14(6):1448-1461. Epub 2016 Feb 4.

Michigan Center for Translational Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Department of Pathology, University of Michigan, Ann Arbor, MI 48109, USA; Howard Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109, USA; Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48109, USA; Department of Urology, University of Michigan, Ann Arbor, MI 48109, USA. Electronic address:

View Article and Find Full Text PDF
February 2016

KRAS insertion mutations are oncogenic and exhibit distinct functional properties.

Nat Commun 2016 Feb 8;7:10647. Epub 2016 Feb 8.

Department of Pediatrics, University of California, 1450 3rd St, San Francisco, California 94158, USA.

View Article and Find Full Text PDF
February 2016

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma.

Sci Signal 2015 Aug 18;8(390):ra82. Epub 2015 Aug 18.

Molecular Oncology Laboratory, Peter MacCallum Cancer Centre, St. Andrew's Place, East Melbourne, Victoria 3002, Australia. Oncogenic Signalling and Growth Control Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. Sir Peter MacCallum Department of Oncology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria 3010, Australia. Cancer Therapeutics Program, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3002, Australia. Department of Pathology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Victoria 3010, Australia.

View Article and Find Full Text PDF
August 2015

Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.

N Engl J Med 2015 Jul;373(5):428-37

From Memorial Sloan Kettering Cancer Center (W.D.T., J.H.H.) and Weill Cornell Medical College (W.D.T.) - both in New York; University of California, Los Angeles, Medical Center, Los Angeles (Z.A.W., B.C., A.S.S.), Plexxikon, Berkeley (P.N.I., C.Z., J.Z., G.H., Y.Z., E.A.B., G.V., L.S., P.S., H.N., M.J.K., A.M., G.T., R.S., C.G., B.L.W., P.H., K.N., H.H.H., P.S.L., S.T.-S., G.B.), and Stanford University School of Medicine, Stanford (M.R.) - all in California; Evergreen Hematology and Oncology, Spokane, WA (S.P.A.); University of Pennsylvania School of Medicine, Philadelphia (A.P.S.); Rocky Mountain Cancer Centers, Denver (A.L.C.); Dana-Farber Cancer Institute (G.I.S., A.J.W.) and Massachusetts General Hospital (E.L.K.) - both in Boston; Vanderbilt University Medical Center, Nashville (V.L.K., I.P.); Virginia G. Piper Cancer Center at Scottsdale Healthcare-Translational Genomics Research Institute (TGen), Scottsdale, AZ (D.D.V.H., G.J.W., R.K.R.); and Spire Sciences, Boca Raton, FL (C.P.).

View Article and Find Full Text PDF
July 2015

Inhibition of colony stimulating factor-1 receptor improves antitumor efficacy of BRAF inhibition.

BMC Cancer 2015 May 5;15:356. Epub 2015 May 5.

Department of Molecular and Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.

View Article and Find Full Text PDF
May 2015

CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy.

Cancer Res 2015 Mar 3;75(6):950-62. Epub 2015 Mar 3.

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California. Department of Urology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California.

View Article and Find Full Text PDF
March 2015

Mapping the molecular determinants of BRAF oncogene dependence in human lung cancer.

Proc Natl Acad Sci U S A 2014 Feb 3;111(7):E748-57. Epub 2014 Feb 3.

Departments of Medicine and Epidemiology and Biostatistics and Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94158.

View Article and Find Full Text PDF
February 2014

Drug discovery: Pocket of opportunity.

Nature 2013 Nov 20;503(7477):475-6. Epub 2013 Nov 20.

Plexxikon Inc., Berkeley, California 94710, USA.

View Article and Find Full Text PDF
November 2013

Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.

Cancer Res 2014 Jan 18;74(1):153-161. Epub 2013 Nov 18.

Department of Molecular and Medical Pharmacology, University of California Los Angeles, 10833 Le Conte Avenue, Los Angeles, CA 90095 (UCLA).

View Article and Find Full Text PDF
January 2014

Recurrent BRAF kinase fusions in melanocytic tumors offer an opportunity for targeted therapy.

Pigment Cell Melanoma Res 2013 Nov 19;26(6):845-51. Epub 2013 Aug 19.

Departments of Dermatology and Pathology and Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, CA, USA.

View Article and Find Full Text PDF
November 2013

Defective K-Ras oncoproteins overcome impaired effector activation to initiate leukemia in vivo.

Blood 2013 Jun 1;121(24):4884-93. Epub 2013 May 1.

Department of Pediatrics and Division of Pediatric Hematology and Oncology, School of Medicine, University of California-San Francisco, CA, USA.

View Article and Find Full Text PDF
June 2013

CSF1R signaling blockade stanches tumor-infiltrating myeloid cells and improves the efficacy of radiotherapy in prostate cancer.

Cancer Res 2013 May 15;73(9):2782-94. Epub 2013 Feb 15.

Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095-1735, USA.

View Article and Find Full Text PDF
May 2013

Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Clin Cancer Res 2013 Feb 18;19(3):657-67. Epub 2012 Dec 18.

Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, and Graduate School of Biomedical Sciences, University of Texas, Houston, TX 77030, USA.

View Article and Find Full Text PDF
February 2013

Neurofibroma-associated macrophages play roles in tumor growth and response to pharmacological inhibition.

Acta Neuropathol 2013 Jan 26;125(1):159-68. Epub 2012 Oct 26.

Division of Human Genetics, Cincinnati Children's Hospital Medical Center, 3333 Burnet Avenue, Cincinnati, OH 45229, USA.

View Article and Find Full Text PDF
January 2013

Vemurafenib: the first drug approved for BRAF-mutant cancer.

Nat Rev Drug Discov 2012 Nov 12;11(11):873-86. Epub 2012 Oct 12.

Plexxikon, 91 Bolivar Drive, Berkeley, California 94710, USA.

View Article and Find Full Text PDF
November 2012

Interrogating the kinome.

Nat Biotechnol 2011 Nov 8;29(11):981-3. Epub 2011 Nov 8.

View Article and Find Full Text PDF
November 2011

Setting up a kinase discovery and development project.

Authors:
Gideon Bollag

Curr Top Microbiol Immunol 2012 ;355:3-18

Plexxikon Inc, Berkeley, CA 94710, USA.

View Article and Find Full Text PDF
August 2014

Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.

Neoplasia 2010 Aug;12(8):637-49

Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.

View Article and Find Full Text PDF
August 2010

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Nature 2010 Mar;464(7287):427-30

Program in Molecular Pharmacology and Chemistry and Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

View Article and Find Full Text PDF
March 2010

Scaffold-based design of kinase inhibitors for cancer therapy.

Curr Opin Genet Dev 2010 Feb 20;20(1):79-86. Epub 2009 Nov 20.

Plexxikon Inc., 91 Bolivar Dr., Berkeley, CA 94710, United States.

View Article and Find Full Text PDF
February 2010

Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells.

J Clin Endocrinol Metab 2010 Jan 30;95(1):450-5. Epub 2009 Oct 30.

Dipartimento di Biologia e Patologia Cellulare e Molecolare, Universita Federico II, 80131 Naples, Italy.

View Article and Find Full Text PDF
January 2010

Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice.

Proc Natl Acad Sci U S A 2008 Dec 17;105(48):18895-900. Epub 2008 Nov 17.

Diabetes Center and the Department of Medicine, University of California, San Francisco, CA 94143, USA.

View Article and Find Full Text PDF
December 2008

Biochemical and functional characterization of germ line KRAS mutations.

Mol Cell Biol 2007 Nov 17;27(22):7765-70. Epub 2007 Sep 17.

Department of Pediatrics, University of California, 513 Parnassus Avenue, HSE 302, San Francisco, California 94143, USA.

View Article and Find Full Text PDF
November 2007

Hyperactive Ras in developmental disorders and cancer.

Nat Rev Cancer 2007 Apr;7(4):295-308

Department of Pediatrics, University of California, 513 Parnassus Avenue, Room HSE-302, San Francisco, California 94143, USA.

View Article and Find Full Text PDF
April 2007

Deregulated Ras signaling in developmental disorders: new tricks for an old dog.

Curr Opin Genet Dev 2007 Feb;17(1):15-22

Department of Pediatrics, University of California, 513 Parnassus Avenue, Room HSE-302, San Francisco, CA 94143, USA.

View Article and Find Full Text PDF
February 2007

Sending out an SOS.

Nat Genet 2007 Jan;39(1):8-9

View Article and Find Full Text PDF
January 2007

Germline mutations in components of the Ras signaling pathway in Noonan syndrome and related disorders.

Cell Cycle 2006 Aug 1;5(15):1607-11. Epub 2006 Aug 1.

Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany.

View Article and Find Full Text PDF
August 2006

Phosphodiesterase-4 as a potential drug target.

Expert Opin Ther Targets 2005 Dec;9(6):1283-305

Plexxikon, Inc., 91 Bolivar Drive, Berkeley, CA 94710, USA.

View Article and Find Full Text PDF
December 2005

The phosphodiesterase PDE4B limits cAMP-associated PI3K/AKT-dependent apoptosis in diffuse large B-cell lymphoma.

Blood 2005 Jan 26;105(1):308-16. Epub 2004 Aug 26.

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA.

View Article and Find Full Text PDF
January 2005

Raf pathway inhibitors in oncology.

Curr Opin Investig Drugs 2003 Dec;4(12):1436-41

Plexxikon Inc., 91 Bolivar Drive, Berkeley, CA 94710, USA.

View Article and Find Full Text PDF
December 2003

GTPase activating proteins: critical regulators of intracellular signaling.

Biochim Biophys Acta 2002 Mar;1602(1):23-45

Department of Pediatrics and Comprehensive Cancer Center, 513 Parnassus Ave., Room HSE-302, University of California, San Francisco, CA 94143-0519, USA.

View Article and Find Full Text PDF
March 2002